|
|
Upfront Briefing
Roche brought the cleanest tape this morning: a phase III head-to-head KRAS G12C win is the sort of result that can reshuffle an oncology lane in a hurry. Elsewhere, the FDA cleared Orca Bio's Tregzi — the first Treg cell therapy ever to reach market — while Brussels handed Novartis an EU nod for Itvisma across the older SMA crowd. Two one-time therapies, two very different launch-math problems.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,483.2 |
(0.2%) |
+9.1% |
| Nasdaq 100 |
29,809.1 |
(1.5%) |
+18.3% |
| Russell 2000 |
3,012.6 |
(0.4%) |
+20.1% |
| Healthcare (XLV) |
159.5 |
+0.6% |
+2.6% |
| Biotech (XBI) |
156.6 |
(1.1%) |
+28.8% |
| Nasdaq Biotech (NBI) |
6,561.6 |
0.0% |
+15.0% |
| Clinical Trials (BBC) |
51.5 |
(2.2%) |
+37.0% |
|
- Healthcare outperformed a soft tape — XLV +0.6% while higher-beta biotech gave back ground (XBI (1.1%), clinical-trials BBC (2.2%)); the day's marquee sector catalyst was Roche's positive phase III divarasib head-to-head in KRAS G12C NSCLC, though SIX-listed Roche sits outside the XBI/NBI baskets.
- The broad tape opened Q3 lower as a two-day tech relief rally reversed — the Nasdaq 100 led losses on megacap profit-taking after U.S. equities logged their strongest quarter since 2020.
- Market data: U.S. cash close Wednesday, 1 July 2026.
The Big 3
|
1
|
Roche says phase III divarasib beat KRAS G12C rivals in NSCLC
|
- Divarasib, Roche's KRAS G12C inhibitor, met the primary and key secondary endpoints in phase III Krascendo 1, with clinically meaningful and statistically significant PFS and OS gains versus approved KRAS G12C inhibitors in previously treated NSCLC.
- Why it matters: A positive phase III head-to-head readout is a major strategic win for Roche in KRAS G12C, but investors still need the actual hazard ratios, median PFS/OS and safety profile before fully resetting peak-sales and share assumptions. If detailed data hold up, divarasib could materially improve Roche's leverage in a market now defined by Amgen and BMS.
-
Source:
Roche
|
|
2
|
FDA approves Orca Bio's Tregzi for transplant outcomes
|
-
The FDA approved Tregzi (Orca-T), Orca Bio's precision-engineered allogeneic cell therapy, for matched-donor stem-cell transplant in adults with blood cancers — the first approval of a regulatory T cell (Treg)–based therapy. In the pivotal Precision-T trial (n=187), one-year chronic GVHD–free survival was 78% vs 38% for standard transplant.
-
Why it matters: First-in-modality is the story, not the label. A Treg graft that preserves graft-versus-leukemia while cutting chronic GVHD (13% vs 44%) and non-relapse mortality (3% vs 13%) is a template the whole transplant field will chase. The catch for anyone trying to play it: Orca is private (Series F, Lightspeed-led), so there's no clean listed exposure — Fierce is already floating an IPO. Watch the $428k WAC against transplant-center economics, and the matched-donor-only label, which caps the initial pool and leaves haplo/mismatched settings open to the next entrant.
-
Source:
STAT
-
More:
Fierce Pharma;
BioSpace
|
|
3
|
EU approves Novartis's Itvisma for the broad SMA population
|
-
The European Commission approved Itvisma (intrathecal onasemnogene abeparvovec) for children 2+, teens and adults with 5q SMA — the first and only one-time gene replacement therapy cleared for this broad SMA population in the EU, backed by the pivotal STEER study.
-
Why it matters: This is the older-patient half of Novartis's SMA franchise. Itvisma's intrathecal dosing pushes gene replacement past the infant Zolgensma population Novartis already owns, so the near-term read is franchise defense against chronic dosers Biogen (Spinraza) and Roche (Evrysdi) rather than a fresh market. EU payer pricing on a one-and-done therapy competing with recurring-revenue rivals is the swing factor, and uptake among treatment-experienced adults — many stable on maintenance drugs — is the commercial question STEER now has to sell.
-
Source:
Novartis
|
Everything Else that broke
- Merck scrapped Phase 2 Alzheimer's asset MK-1167 from partner Neuphoria. — BioSpace
- FDA warned Sanofi's Genzyme Irish site over quality and data-related issues. — BioSpace
- WuXi AppTec sought a preliminary injunction over its China military list designation. — BioSpace
- Skyhawk posted 12-month phase 1/2 SKY-0515 trends across all four cUHDRS subcomponents in Huntington's disease. — BioWorld
- FDA expanded Vertex and CRISPR Therapeutics' Casgevy to patients aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. — FDA
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Insilico Medicine signed an AI drug-discovery collaboration with Takeda across Takeda's therapeutic areas — $60M upfront, up to $600M in milestones plus tiered royalties, using Insilico's Pharma.AI platform. — Fierce Biotech
- Abbisko and AstraZeneca struck a strategic collaboration to run a Phase I/II trial of Abbisko's oral PD-L1 inhibitor lumipodlin (ABSK043) with Tagrisso (osimertinib) in EGFR-mutated, PD-L1-positive NSCLC; no financial terms disclosed. — PR
- Ribo and Madrigal hit a first major milestone in their siRNA collaboration for MASH. — PR
- AlzeCure out-licensed global rights to its NeuroRestore platform and lead Alzheimer's candidate ACD856 to Denmark's QuantumCell — $12M upfront (incl. a $5M equity stake at a 30% premium) plus development/commercial milestones exceeding $2.2B and tiered royalties. — Fierce Biotech
- Junshi licensed roconkibart, an IL-17A asset, to Fosun Wanbang in Greater China. — PR
- Nona and Lonza partnered on single-domain antibody BBB-crossing technology for CNS diseases. — PR
VC / Private Financings
- No notable private biotech financings since yesterday.
IPOs / Follow-Ons
- Elicio priced a $15M registered direct to fund planned Phase 1 development of ELI-002 7P in metastatic PDAC. — PR
- Abivax expanded its ADS offering to $920M after full exercise of the underwriters' option. — PR
Academic Corner - A genome-scale CRISPRi atlas mapped transcriptional regulation in human induced pluripotent stem cells. — Nature Biotech
- Nature Medicine linked faster biological aging markers to rising risk of early-onset solid cancers. — Nature Medicine
|
That'll do it for today's brief. Go enjoy the Fourth — hot dogs, fireworks, and zero earnings calls. We'll be back once the grill cools down. — BioBucks Team
|
|
|
